Analysis of small molecule tyrosine kinase inhibitor combined with monoclonal antibody of programmed death receptor-1 in treatment of patients with advanced malignant tumors of digestive system

MI Zhihui; QU Jinglei; QU Xiujuan; TENG Zan; CHEN Ying; SONG Na

doi:10.7619/jcmp.20211628

Journal of Clinical Medicine in Practice > 2021 > 25(18): 60-65. > DOI: 10.7619/jcmp.20211628

MI Zhihui, QU Jinglei, QU Xiujuan, TENG Zan, CHEN Ying, SONG Na. Analysis of small molecule tyrosine kinase inhibitor combined with monoclonal antibody of programmed death receptor-1 in treatment of patients with advanced malignant tumors of digestive system[J]. Journal of Clinical Medicine in Practice, 2021, 25(18): 60-65. DOI: 10.7619/jcmp.20211628

Citation:

PDF (1365 KB)

Analysis of small molecule tyrosine kinase inhibitor combined with monoclonal antibody of programmed death receptor-1 in treatment of patients with advanced malignant tumors of digestive system

Department of Oncology, the First Hospital Affiliated to China Medical University, Shenyang, Liaoning, 110001

More Information

Received Date: April 16, 2021
Available Online: October 19, 2021
Published Date: September 27, 2021

Graphical Abstract

Abstract

Abstract

Objective To analyze the efficacy and safety of small molecule tyrosine kinase inhibitor (TKI) combined with monoclonal antibody of programmed death receptor-1 (PD-1) in the treatment of patients with advanced malignant tumors of digestive system.
Methods The efficacy and adverse reactions, tumor growth rate and correlation between adverse reactions and efficacy in the patients with advanced malignant tumors of digestive system by combined treatment of TKI and monoclonal antibody of PD-1 from March 2019 to February 2021 in the Internal Department of Oncology of the First Hospital of China Medical University were analyzed retrospectively.
Results Among the 30 included patients, 25 patients were available for efficiency evaluation. The objective response rate (ORR) and disease control rate (DCR) of cases with gastric and intestinal cancers were 0 and 58.33% respectively, the ORR and DCR of cases with liver cancer were 50.00% and 100.00% respectively, the ORR and DCR of cases with pancreatic cancer were 33.30% and 100.00% respectively, and the ORR and DCR of cases with esophageal cancer were 50.00% and 100.00% respectively. There were significant correlations between tumor growth rate, immune related adverse events and DCR (P < 0.05).
Conclusion TKI combined with monoclonal antibody of PD-1 shows a certain anti-tumor activity in the treatment of patients with advanced malignant tumors of digestive system, and the patients with liver cancer are prone to have more benefits from combined treatment. In the course of combined therapy, patients with slow tumor growth rate have better curative effect.
- tyrosine kinase inhibitor,
- programmed death receptor-1,
- malignant tumors,
- tumor growth rate,
- objective response rate,
- disease control rate

FullText(HTML)

References (28)

References

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	GHAHREMANLOO A, SOLTANI A, MODARESI S, et al. Recent advances in the clinical development of immune checkpoint blockade therapy[J]. Cellular Oncology, 2019, 42(5): 609-626. doi: 10.1007/s13402-019-00456-w
[3]	HUANG Y, STYLIANOPOULOS T, DUDA D G, et al. Benefits of vascular normalization are dose and time dependent-letter[J]. Cancer Research, 2013, 73(23): 7144-7146. doi: 10.1158/0008-5472.CAN-13-1989
[4]	KATO K, MASUISHI T, FUSHIKI K, et al. Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer[J]. Journal of Clinical Oncology, 2019, 37(Suppl 4): 84-84. http://www.sciencedirect.com/science/article/pii/S2059702921001393
[5]	FUKUOKA S, HARA H, TAKAHASHI N, et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)[J]. Journal of Clinical Oncology, 2019, 37(Suppl 15): 2522-2522. http://www.researchgate.net/publication/333406836_Regorafenib_plus_nivolumab_in_patients_with_advanced_gastric_GC_or_colorectal_cancer_CRC_An_open-label_dose-finding_and_dose-expansion_phase_1b_trial_REGONIVO_EPOC1603
[6]	LWIN Z, GOMEZ-ROCA C, SAADA-BOUZID E, et al. LBA41 LEAP-005: Phase Ⅱ study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours[J]. Annals of Oncology, 2020, 31(Suppl 4): S1170. http://www.sciencedirect.com/science/article/pii/S0923753420423531
[7]	XU J, ZHANG Y, JIA R, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study[J]. Clin Cancer Res: an official journal of the American Association for Cancer Research, 2019, 25(2): 515-523. doi: 10.1158/1078-0432.CCR-18-2484
[8]	FOLKMAN J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1196. doi: 10.1056/NEJM197111182852108
[9]	JAIN, RAKESH K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia[J]. Cancer Cell, 2014, 26(5): 605-622. doi: 10.1016/j.ccell.2014.10.006
[10]	HENDRY S A, FARNSWORTH R H, SOLOMON B, et al. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment[J]. Frontiers in immunology, 2016, 7: 621.
[11]	RINDERT M, MASSIMILIANO M, GABRIELE B. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer[J]. Seminars in Cancer Biology, 2018, 52(2): 107-116. http://www.onacademic.com/detail/journal_1000040435717410_1ae9.html
[12]	VORON T, COLUSSI O, MARCHETEAU E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8⁺ T cells in tumors[J]. Journal of Experimental Medicine, 2015, 212(2): 139-148. doi: 10.1084/jem.20140559
[13]	HOFF S, GRVNEWALD S, RSE L, et al. 1198PImmunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer[J]. Annals of Oncology, 2017, 28(Suppl 5): 1131-1138.
[14]	WANG C, CHEVALIER D, SALUJA J, et al. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer[J]. The Oncologist, 2020, 25(8): 1188-1194. doi: 10.1634/theoncologist.2020-0161
[15]	GIBNEY G T, WEINER L M, ATKINS MBJLO. Predictive biomarkers for checkpoint inhibitor-based immunotherapy[J]. Lancet Oncology, 2016, 17(12): 542-551. doi: 10.1016/S1470-2045(16)30406-5
[16]	CHENG A L, HSU C, CHAN S L, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma[J]. Journal of Hepatology, 2020, 72(2): 307-319. doi: 10.1016/j.jhep.2019.09.025
[17]	SAMSTEIN R M, LEE C H, SHOUSHTARI A N, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types[J]. Nature Genetics, 2019, 51(2): 202-206. doi: 10.1038/s41588-018-0312-8
[18]	MASUISHI T, TANIGUCHI H, KAWAKAMI T, et al. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer[J]. ESMO Open, 2019, 4(6): 000584. http://www.sciencedirect.com/science/article/pii/S2059702920300934
[19]	PHILIPS G K, ATKINS M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies[J]. International Immunology, 2015, 27(1): 39-46. doi: 10.1093/intimm/dxu095
[20]	GUNTURI A, MCDERMOTT D F. Nivolumab for the treatment of cancer[J]. Expert Opinion on Investigational Drugs, 2015, 24(2): 253-60. doi: 10.1517/13543784.2015.991819
[21]	TOPALIAN S L, DRAKE C G, PARDOLL D M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity[J]. Current Opinion in Immunology, 2012, 24(2): 207-212. doi: 10.1016/j.coi.2011.12.009
[22]	GETTINGER S N, HORN L, GANDHI L, et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer[J]. Journal of Clinical Oncology, 2016, 33(18): 2004-2012. http://pubmedcentralcanada.ca/pmcc/articles/PMC4672027/
[23]	MCDERMOTT D F, DRAKE C G, SZNOL M, et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab[J]. Journal of Clinical Oncology, 2015, 33(18): 2013-2020. doi: 10.1200/JCO.2014.58.1041
[24]	TOPALIAN S L, SZNOL M, MCDERMOTT D F, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J]. Journal of Clinical Oncology, 2014, 32(10): 1020-1030. doi: 10.1200/JCO.2013.53.0105
[25]	GAUCI M L, LANOY E, CHAMPIAT S, et al. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation[J]. Clinical Cancer Research, 2019, 25(3): 946-956. doi: 10.1158/1078-0432.CCR-18-0793
[26]	DIAZ L A, LE D T, YOSHINO T, et al. KEYNOTE-177: First-line, open-label, randomized, phase Ⅲstudy of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma[J]. 2016.
[27]	Chen L T, Kang Y K, Satoh T, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data[J]. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020, 23(3): 510-519. http://newmed.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM31863227
[28]	POSTOW M A. Managing immune checkpoint-blocking antibody side effects[J]. American Society of Clinical Oncology Educational Book, 2015, 35(1): 76-83. http://pdfs.semanticscholar.org/c4f8/f8c7782857e790fa07e0dbf63df979e78a86.pdf

Cited By

Cited by

Periodical cited type(6)

1.	杨可非，刘文靖，周新尧，姜泉. 基于“体脏合痹”理论探讨干燥综合征病机论治. 中国中医基础医学杂志. 2025(02): 236-240 .
2.	邹怡萌，邹纯朴，陈晓，朱杨壮壮，苏琳，胥孜杭. 基于“肺主皮毛”理论的中西联系与思考. 北京中医药大学学报. 2024(01): 42-48 .
3.	张盈，杨波，蔡新利，王霜，王迎春. 干燥综合征患者血清HMGB1、Progranulin与NK细胞亚群和间质性肺疾病的关系研究. 现代生物医学进展. 2024(20): 3867-3869 .
4.	陈嘉琪，杨建英，吴子华，张丽宁，张燕，胡琪，贺倩，黄子玮，余新波，罗静，陶庆文. 原发性干燥综合征合并间质性肺病的中医证候特点及相关因素分析. 中国实验方剂学杂志. 2023(08): 66-72 .
5.	彭艳茹，闫世艳，罗成，张宁，李睿，王玉光. 中医药联合西医治疗干燥综合征相关间质性肺疾病的临床疗效和安全性的系统评价. 中国医院用药评价与分析. 2023(08): 980-984 .
6.	王菲，时美红. 原发性干燥综合征患者唇腺组织中BTB/POZ结构域蛋白7及基质金属蛋白酶-9的表达与自身抗体的关系. 实用临床医药杂志. 2022(21): 98-102 . 本站查看

Other cited types(0)

Get Citation

PDF

XML

Article views PDF downloads Cited by(6)

Turn off MathJax

Article Contents

Abstract

References

Analysis of small molecule tyrosine kinase inhibitor combined with monoclonal antibody of programmed death receptor-1 in treatment of patients with advanced malignant tumors of digestive system

Abstract

References

Cited by

Periodical cited type(6)

Other cited types(0)

Catalog

Export File

Citation

Format

Content